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We report a genomewide linkage study of type 2 diabetes (T2D [MIM 125853]) in the Icelandic population. A list
of type 2 diabetics was cross-matched with a computerized genealogical database clustering 763 type 2 diabetics
into 227 families. The diabetic patients and their relatives were genotyped with 906 microsatellite markers. A
nonparametric multipoint linkage analysis yielded linkage to 5q34–q35.2 (LOD p 2.90, ) in all54Pp 1.29# 10
diabetics. Since obesity, here defined as body mass index (BMI) 30 kg/m2, is a key risk factor for the development
of T2D, we studied the data either independently of BMI or by stratifying the patient group as obese (BMI 30)
or nonobese (BMI !30). A nonparametric multipoint linkage analysis yielded linkage to 5q34–q35.2 (LOD p
3.64, ) in the nonobese diabetics. No linkage was observed in this region for the obese diabetics.55Pp 2.12# 10
Linkage analysis conditioning on maternal transmission to the nonobese diabetics resulted in a LOD score of 3.48
( ) in the same region, whereas conditioning on paternal transmission led to a substantial drop in55Pp 3.12# 10
the LOD score. Finally, we observed potential interactions between the 5q locus and two T2D susceptibility loci,
previously mapped in other populations.
Introduction
Type 2 diabetes (T2D) is a complex genetic disease, char-
acterized by hyperglycemia due to insulin resistance in
target tissues, that is usually brought to light by coexisting
impairment of insulin secretion. T2D has serious conse-
quences for health, leading to complications such as my-
ocardial infarction, stroke, peripheral arterial occlusive
disease, nephropathy, retinopathy, and neuropathy. In
1995, there were 135 million adults suffering from this
disease worldwide, and the prevalence is increasing. It is
estimated that close to 300 million will develop diabetes
by the year 2025 (King et al. 1998). In the United States
alone, it is estimated that there are 16 million diabetics,
and approximately half of them remain undiagnosed
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(Moneva and Dagogo-Jack 2002). In fact, the average
delay between onset of disease and diagnosis of T2D in
the U.S. is estimated to be 10 years. Early diagnosis and
treatment of T2D is important, as this allows marked
reduction in complications (UKPDS33 1998), and recent
studies have shown that lifestyle modifications are effec-
tive in preventing conversion of prediabetes (Knowler et
al. 2002).
Both genetic and environmental factors influence dis-
ease susceptibility. Obesity is a leading risk factor, but
aging, ethnicity, Western-style diet, and a sedentary life-
style are also important. Individuals from families with
a history of diabetes are at a higher risk of developing
the disease (Rotter et al. 1992; Rewers and Hamman
1995; Foster 1998). The high rate of concordance be-
tween MZ twins further suggests the role of genetic
components in the pathogenesis of T2D (Rotter et al.
1992; Rewers and Hamman 1995 and references
therein; Medici et al. 1999; Poulsen et al. 1999).
Variants in six genes have been identified that lead to
maturity-onset diabetes of the young (MODY [MIM
606391]), which is an early-onset monogenic form of
type 2 diabetes. MODY 1–6 (MIM 125850, 125851,
600496, 606392, 604284, 606394) result from muta-
tions in HNF4a (Yamagata et al. 1996a), glucokinase
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(Froguel et al. 1992), HNF1a (Yamagata et al. 1996b),
IPF1 (Stoffers et al. 1997), HNF1b (Horikawa et al.
1997), and NEUROD1 (Malecki et al. 1999), respec-
tively. Mutations in any of the six genes affect glucose-
stimulated insulin secretion from pancreatic islet b-cells,
but they do not appear to play a role in the more com-
mon forms of T2D.
A number of genes with potential roles in the path-
ogenesis of diabetes have been screened for mutations.
Mutations have been identified in genes such as the in-
sulin receptor (MIM 147670), but they are responsible
for severe forms of diabetes with Mendelian inheritance
and account for only a very small number of cases (Kahn
et al. 1996). There have been numerous studies of as-
sociations of candidate genes with T2D. Most show
mild or modest association with the disease. One study
(Altshuler et al. 2000) reviewed some of the association
work that had been done at that point and concluded
that association with only 1 of 16 reported genes
met the standard of replication. In a meta-analysis of
previous studies, Altshuler et al. concluded that the
Pro12Ala polymorphism in PPARg (MIM 601487) is
associated with T2D, conferring a relative risk of 1.2.
Genomewide scans have been performed in a variety
of populations, revealing a number of significant or sug-
gestive diabetes susceptibility loci. Studies in Mexican
Americans have mapped genes to 2q37 (Hanis et al.
1996), 15q21 (Cox et al. 1999), 10q26 (Duggirala et
al. 1999), and 3p (Ehm et al. 2000). In Pima Indians,
linkages have been observed with 1q21–23 and 11q23–
q25 (Hanson et al. 1998). In white populations, linkages
have been established with 12q24 (Mahtani et al. 1996)
and 9p13–q21 (Lindgren et al. 2002a) in Finns,
1q21–q23 in Americans in Utah (Elbein et al. 1999),
3q27-qter in French families (Vionnet et al. 2000), and
18p11 in Scandinavians (Parker et al. 2001). A locus
was reported, in indigenous Australians, on 2q24.3
(Busfield et al. 2002). Some of the loci mentioned above
have been replicated. There are also many reports of
weaker linkages to other regions in the genome.
Only one of the genomewide scans has resulted in the
isolation of a gene that is thought to contribute to the
late-onset form of diabetes (Horikawa et al. 2000).
Here, the intronic variation UCSNP-43 (G/A) in the
calpain 10 gene (CAPN10 [MIM 605286]) at the
NIDDM1 locus, was shown to be significantly associ-
ated with diabetes susceptibility among Mexican Amer-
icans. Association to UCSNP-43 has been replicated
only in some follow-up studies (Baier et al. 2000; Evans
et al. 2001; Tsai et al. 2001; Rasmussen et al. 2002),
but variants in CAPN10 have been associated with an
increased risk of T2D in some populations (Horikawa
et al. 2000; Evans et al. 2001; Malecki et al. 2001;
Cassell et al. 2002; Garant et al. 2002; Lynn et al. 2002;
Orho-Melander et al. 2002; Wang et al. 2002). More-
over, the at-risk allele was shown to be associated with
impaired regulation of glucose-induced insulin secretion
(Sreenan et al. 2001; Lynn et al. 2002) and decreased
rate of insulin-stimulated glucose disposal in muscle
(Baier et al. 2000; Sreenan et al. 2001).
This paper reports a genomewide search for causative
genes in T2D in Iceland, stratified according to BMI.
The prevalence of T2D in Iceland is relatively low, at
2.5% (Vilbergsson et al. 1997). Accordingly, ∼5,000
people in Iceland aged 134 years have T2D. However,
only 60% of these individuals have been diagnosed.
Approximately 17% of the adult population in Iceland
is obese (BMI30), and the incidence of obesity among
children and adolescents is increasing dramatically (the
International Obesity Task Force). Given the strong as-
sociation of obesity with diabetes, we expect the inci-
dence of T2D to increase significantly in Iceland over
the next decade.
Subjects and Methods
Patients
This study was approved by the Data Protection Com-
mission of Iceland and the National Bioethics Commit-
tee of Iceland. All patients and their relatives who par-
ticipated in the study gave informed consent. All
personal identifiers associated with blood samples, med-
ical information, and genealogy were first encrypted by
the Data Protection Commission, using a third-party en-
cryption system (Gulcher et al. 2000).
This study was based on a list of 2,400 diabetics di-
agnosed either through a long-term epidemiology study
done at the Icelandic Heart Association over the past 30
years or at one of two major hospitals in Reykjavı´k over
the past 12 years. Two-thirds of these patients are alive,
representing about half of the population of known di-
abetics. The majority of the patients have been contacted
for this study, and the cooperation rate exceeded 90%.
All participants answered a questionnaire, including
questions about medication and age at diagnosis. Their
height (m) and weight (kg) were measured to calculate
BMI. For known diabetics, dietary treatment with or
without oral glucose-lowering agents identified T2D. In-
dividuals currently treated with insulin were classified
as having T2D if they were also using or had previously
used oral glucose-lowering agents. The majority of pa-
tients on medication take oral glucose-lowering agents,
and only a few patients need insulin. Although the prev-
alence of LADA (latent autoimmune diabetes in adults
[MIM 222100, 138275]) in Iceland is unknown, this is
generally !10% in Europeans (Tuomi et al. 1999). For
hitherto undiagnosed individuals, the diagnosis of T2D
and impaired fasting glucose (IFG) was based on the
criteria set by the American Diabetes Association (Expert
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Table 1
T2D and IFG Patients Included in the Genomewide Analysis
RESULTS FOR PATIENT GROUP
All Patients T2D IFG
Gender (male/female) 423/340 391/312 32/28
Age (years, )mean SD 68.5 12.2 68.9 11.7 63.2 16.6
BMI (kg/m2, )mean SD 29.1 4.8 29.2 4.9 28.3 4.5
Committee on the Diagnosis and Classification of Dia-
betes Mellitus 1997). Thus, T2D denotes all known di-
abetics, as well as all previously undiagnosed individuals
with fasting serum glucose 7 mM on two separate
occasions. A diagnosis of IFG was given to individuals
with fasting serum glucose between 6.1 and 6.9 mM on
two occasions or 17 mM on an initial measurement and
between 6.1 and 6.9 on a second measurement. The
criterion for being recalled was an initial fasting serum
glucose6.1 mM. Oral glucose–tolerance tests (OGTT)
were not done, but known diabetics might have been
previously diagnosed by an OGTT. Although the diag-
nosis of MODY includes onset before the age of 25
years, this is not part of the definition of T2D. In the
current study, all patients had an adult onset, with only
a small percentage (!3%) of T2D patients diagnosed
before the age of 35 years, thus reducing the likelihood
that they have MODY. We, however, can not fully ex-
clude LADA, as referred to above.
The average age of the diabetic patients is 68.5 years
(table 1). Therefore, very few patients had a parent or
parents who were alive and/or were able to participate
in the study. In all, 60 fathers and 98 mothers partici-
pated in the study and were genotyped. Thirteen patients
had both parents affected with T2D. The diabetic status
of nonparticipating parents is unknown.
Phenotypes and Pedigrees
Blood samples were collected from 964 individuals
with T2D and 203 individuals with IFG. The patients
with T2D were treated as probands and were clustered
into families by use of our computerized genealogy da-
tabase, with the criterion that each proband is related
to at least one other proband by six or fewer meiotic
events. The IFG patients were added to the families if
they were related to a proband by three or fewer meiotic
events. The rationale behind this was to include as many
patients as possible in the study. Impaired fasting glucose
is an intermediate diagnosis and a prediabetic state, and
we reasoned that the more closely related these patients
are to the diabetics, the more likely they are to develop
the disease. Patients who clustered within extended fam-
ilies with multiple affected individuals were genotyped
first; a total of 772 individuals—705 patients with T2D
and 67 patients with IFG. The 259 patients with T2D
who do not cluster within six meiotic events were ge-
notyped later, since they did not contribute to the linkage
analysis.
The families were checked for relationship errors by
comparison of the identity-by-state (IBS) distribution for
the set of 906 markers, for each pair of related and
genotyped individuals, to a reference distribution cor-
responding to the particular degree of relatedness re-
flected in the genealogy database. The reference distri-
butions were constructed from a large subset of the
Icelandic population. Individuals were excluded from
the study if their relationship with the rest of the family
was inconsistent with the relationship specified in the
genealogy database. The remaining material that was
available for the study consisted of 763 patients (table
1) in 227 families, together with 764 genotyped relatives.
Of the patients, 703 were confirmed patients with T2D
and 60 were confirmed patients with IFG.
Stratification of Patients Based on BMI Values
The patients were classified into two subgroups based
on their BMI values: nonobese diabetics were defined as
patients with BMI !30, and obese diabetics are patients
who have BMI 30 (obesity is defined as BMI 30; see
Bray [1987]). For each linkage study, the two subgroups
were considered separately. Thus, we clustered by af-
fected status (T2D) independently of BMI, and then we
selected a phenotype on the basis of BMI, as described
above. In other words, in a genome scan that uses non-
obese diabetics, the allele sharing of obese diabetics does
not contribute to the linkage. By selecting a specific sub-
phenotype for linkage analysis, some families no longer
contain a pair of related patients classified as affecteds
and hence do not contribute to the linkage analysis. Ta-
ble 2 summarizes the number of families and patients
who contribute to each of the three patient sets used.
Genomewide Scan
A genomewide scan was performed on 772 patients
and their relatives. Nine patients were excluded because
of inheritance errors, so the linkage analysis was per-
formed with 763 patients and 764 relatives. The pro-
cedure was as described in a recent linkage study in
stroke (Gretarsdottir et al. 2002). In short, the DNA
was genotyped with our framework marker set of 906
microsatellite markers, with an average resolution of 4
cM. Alleles were called automatically with the TrueAllele
program (Cybergenetics), and the program DecodeGT
was used to fractionate according to quality and to edit
the called genotypes (Palsson et al. 1999). The popu-
lation allele frequencies of the markers were constructed
from a cohort of 130,000 Icelanders who had partici-
pated in genomewide studies of various disease projects
at deCODE Genetics. Additional markers were geno-
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Table 2
Numbers of Patients, Pairs of Patients, and Families with T2D and IFG Contributing to the Linkage
Analysis
Phenotypes Total No. of Patients
No. of Families
Contributing to
the Analysis
No. of Patients
Contributing to
the Analysis
No. of Pairs
Contributing to
the Analysis
All diabetics 763 227 763 1,213
Obese diabetics 296 92 219 215
Nonobese diabetics 467 154 413 482
NOTE.—The number of families included in the analysis of the obese and nonobese subphenotypes
does not add up to the number of families when the material is analyzed as a whole, as some families
may include pairs of related obese patients and pairs of related nonobese patients. Likewise, not all
patients are related to another patient of the same subphenotype, and such patients are excluded from
the analysis of the subphenotypes.
typed within the loci on chromosomes 5q, 10q, and 12q
to increase the information on identity by descent within
the families. For those markers, at least 180 Icelandic
controls were genotyped to derive the population allele
frequencies.
The additional microsatellite markers that were ge-
notyped within a locus were either publicly available or
designed by us (in-house markers with a DG designation;
see deCODE Genetics Web site). Repeats within the
DNA sequence were identified that allowed us to choose
or design primers that are evenly spaced across the locus.
The identification of the repeats and location with re-
spect to other markers was based on the work of the
physical mapping team at deCODE. The team has reas-
sembled a physical map on the basis of the finger print-
ed contigs (FPC) from Santa Cruz and the published
sequence of the human genome (UCSC Genome
Bioinformatics).
For the markers in the framework map, the genetic
locations were taken from the recently published high-
resolution genetic map (HRGM) constructed at de-
CODE Genetics (Kong et al. 2002). However, only some
of the markers added to the loci on 5q, 10q, and 12q
are included in the HRGM. Markers that are not present
in the HRGM are placed according to their physical
location in the published sequence of the human genome.
The corresponding marker order was verified, and the
intermarker distances were estimated by use of genetic
mapping, on the basis of the familial data collected for
the T2D study. The same methods were used for the
genetic mapping as were used in constructing the HRGM
(Kong et al. 2002). The order of the markers within the
locus on chromosome 5 and the genetic distances be-
tween them can be found on the deCODE Genetics Web
site. The genetic distances have been converted to Ko-
sambi units for the publication, in accordance with the
published deCODE map; however, the actual linkage
calculations were done by use of a Haldane map func-
tion, under the assumption of a no-interference model.
Statistical Methods for Linkage Analysis
Multipoint, affected-only allele-sharing methods were
used in the analyses to assess evidence for linkage. All
results, both the LOD score and the nonparametric link-
age (NPL) score, were obtained by use of the program
Allegro (Gudbjartsson et al. 2000). Our baseline link-
age analysis, as described elsewhere (Gretarsdottir et al.
2002), uses the Spairs scoring function (Whittemore and
Halpern 1994; Kruglyak et al. 1996), the exponential
allele-sharing model (Kong and Cox 1997), and a family
weighting scheme that is halfway, on the log-scale, be-
tween weighting each affected pair equally and weight-
ing each family equally. The information measure we
use is part of the Allegro program output, and the in-
formation value equals zero if the marker genotypes are
completely uninformative and equals one if the geno-
types determine the exact amount of allele sharing by
descent among the affected relatives (Gretarsdottir et al.
2002). We computed the P values two different ways
and here report the less significant result. The first P
value was computed on the basis of large sample theo-
ry; the distribution of approx-Z p 2[log (10)LOD]lr e
imates a standard normal variable under the null hy-
pothesis of no linkage (Kong and Cox 1997). The second
P value was calculated by comparison of the observed
LOD score with its complete data-sampling distribution
under the null hypothesis (Gudbjartsson et al. 2000).
When the data consist of more than a few families, as
is the case here, these two P values tend to be very similar.
The possibility of imprinting effects on the observed
loci was investigated. Implemented in our linkage anal-
ysis program, Allegro, are imprinting-based scoring
functions that allow us to assign weights to allele sharing
specific to parental origin. For example, to investigate
paternal imprinting, the scoring function only considers
the sharing of alleles transmitted to two affected relatives
through their fathers. When these imprinting-based scor-
ing functions were used, sex-specific genetic maps were
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used in the calculations (Kong et al. 2002; Karason et
al. 2003).
Interaction between Loci
To assess the relationship between pairs of loci, and
to identify possible interaction between loci, an analysis
was carried out conditional on the evidence for linkage
at the locus on 5q. We then observed what effect this
had on other loci identified in the genomewide linkage
analysis—that is, on 6q, 10q, and 12q. The positive in-
teractions (e.g., epistasis) were modeled by assigning
weight 0 to families with an NPL score 0. Negative
interactions or heterogeneity were modeled by assigning
weight 0 to families with a linkage score 0 (Cox et al.
1999). The family NPL score was used for calculating
the correlation, as this has a more appropriate distri-
bution (mean 0, variance 1, with no missing informa-
tion) than the LOD score. Furthermore, the family NPL
scores are independent of each other, unlike the family
LOD scores. Where an increase in the LOD score was
observed, the significance is determined by simulations.
A subset of families is selected that corresponds to the
number of families with positive (or negative) NPL score,
and the linkage analysis is repeated using only those
families. This procedure was repeated 1,000 times and
the P value presented is the fraction of the 1,000 sim-
ulations that produced, at the peak locus, a LOD score
greater or equal to that observed when the analysis is
restricted to the families with a positive (or negative)
NPL score.
Results
The genealogy database was used to cluster the patients
confirmed as having T2D into families, in which each
patient was related to at least one other patient by six
or fewer meiotic events. The patients with IFG (see the
“Methods” section) were added to the families if they
were related to a patient with T2D by three or fewer
meiotic events. The genome scan was performed with
763 patients who clustered into 227 families. The mean
separation of affected pairs was 4.9 meiotic events. The
analysis was performed with three phenotypes: all pa-
tients with T2D, nonobese diabetics, and obese diabet-
ics. In the nonobese category were 60% of our patients:
20% with BMI !25 (lean) and 40% with BMI 25 but
!30 (overweight), and in the obese category were 40%
of our patients: 40% have BMI 30. The number of
patients and families in each category is shown in table
2. Figure 1 depicts the allele-sharing LOD scores from
the analysis with the framework marker set. It shows
that the strongest linkage for all T2D is to chromosome
5q. The best LOD scores using the obese diabetics were
1.14 and 1.30 on chromosome 11p (D11S4149 and
D11S928, respectively), 1.05 on chromosome 12q
(D12S346) and 1.31 on chromosome 18p (D18S63).
The results from the analysis with nonobese diabetics
are reported below.
Chromosome 5
A LOD score of 1.84 is observed on chromosome
5q34-q35.2 with the framework marker set when all the
diabetic patients are included in the analysis (fig. 1).
When the linkage analysis is restricted to nonobese di-
abetics, this LOD score increases to 2.81, still with the
framework marker set. The obese diabetics do not show
linkage to this region.
The information on identity by descent in the region
on 5q34–q35.2 was only ∼78%, with the framework
marker set. Thus, an additional 38 microsatellite mark-
ers in a 40-cM region around the peak were genotyped,
which resulted in an increase in the information content
to ∼95%. With the additional markers, the peak LOD
score increased to 3.64 ( ) for the non-5Pp 2.12# 10
obese diabetics (fig. 2). For all of the patients, the peak
LOD score increased to 2.90 ( ). The4Pp 1.29# 10
peak is centered on marker D5S625, and a drop of 1 in
the LOD score is the region determined by the boundary
markers DG5S5 and D5S429, centromeric and telo-
meric, respectively. This region is ∼9 cM in size, and we
estimate it to be ∼3.7 Mb. Markers with the prefix DG5S
are markers that we designed for repeat elements within
the locus and can be found on the deCODE Genetics
Web site (see the “Subjects and Methods” section).
Interactions between Loci
The most prominent additional LOD scores observed
using the nonobese diabetic phenotype were a LOD
score of 1.80 on 6q (marker D6S1569), a LOD score of
1.69 on 10q (marker D10S1773) and a LOD score of
1.44 on 12q (marker D12S366). The interactions be-
tween these three loci and the locus on chromosome 5q
were studied. The families were stratified on the basis
of their family NPL score at the peak marker (D5S625)
on 5q, into families with positive NPL score (63 families
and 191 nonobese diabetics) and families with negative
NPL score (88 families and 246 nonobese diabetics). The
linkage analysis was repeated with those two subgroups
of families separately and LOD score changes at these
three loci were investigated. For two of the loci, an in-
crease in the LOD score was observed. A negative in-
teraction was observed for the locus on chromosome
10q; linkage analysis of the negative-NPL families in-
creased the LOD score to 4.06 at marker D10S1693.
For the locus on chromosome 12q a positive interaction
was observed; linkage analysis of the positive-NPL
families increased the LOD score to 1.91 at marker
Figure 1 Genomewide scan using 906 microsatellite markers. Results are shown for three phenotypes: all type 2 diabetics (black lines),
obese diabetics (red lines), and nonobese diabetics (blue lines). The multipoint LOD score is on the vertical axis, and the centiMorgan distance
from the p-terminus of the chromosome is on the horizontal axis.
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Figure 2 Multipoint allele-sharing LOD score of a portion of chromosome 5 after 38 microsatellite markers have been added to the
framework marker set in a 40-cM interval from 160 cM to 200 cM. The average distance between the markers in the peak reagion is 0.84
cM. Results are shown for the same three phenotypes as in figure 1, and the location of the markers is indicated with green vertical bars at
the top of the figure.
D12S366. The LOD score at the chromosome 6q locus
decreased in both cases.
Additional markers were genotyped within the loci on
chromosomes 10 and 12. Twenty-one additional mark-
ers were genotyped in a 20-cM region around the peak
marker D12S366 on 12q. This raised the information
content in the linkage analysis to ∼97%. Without re-
stricting the analysis to families with a positive NPL
score on chromosome 5q, the LOD score was 1.47, in-
cluding the additional markers now centered at marker
DG12S125 (fig. 3a). However, when the positive-NPL
families were analyzed, the LOD score in the region in-
creased to 2.26, also at DG12S125. The significance of
this increase was examined by 1,000 simulations, se-
lecting 63 families at random each time and repeating
the linkage analysis. Only 20 of 1,000 simulations
( ) resulted in a LOD score that was equal orPp .02
higher than the observed LOD score of 2.26.
An additional 8 markers were genotyped in a 20-cM
region around the peak on 10q. This increased the in-
formation content in the linkage analysis to ∼86%
around the peak region of the locus. The LOD score
was 1.24 when all families with nonobese diabetics were
used (fig. 3b). Analysis restricted to the negative-NPL
families increased the maximum LOD score to 2.79 (still
at marker D10S1693), although this increase is smaller
than what we observed when using only the framework
marker set. The significance of this LOD score was tested
by performing 1,000 simulations. Here, 74 of the 1,000
simulations yielded a maximum LOD score of 2.79 or
higher (i.e., a P value of .074).
Imprinting
The locus on chromosome 5q was affected dramati-
cally when imprinting was considered. The linkage anal-
ysis using only maternal transmission to nonobese dia-
betics gave a LOD score of 3.48 (fig. 4) or Pp
, at marker DG5S45, a shift in location of53.12# 10
2 cM from the peak obtained using all the nonobese
diabetics (see marker map at the deCODE Genetics Web
site). In contrast, when only the paternal transmissions
were considered, the maximum LOD score was 0.53 at
marker DG5S910. Similar numbers of affected pairs are
related through the maternal lineage (194 pairs) and the
paternal lineage (190 pairs).
Furthermore, an effect of imprinting was observed on
the loci on chromosome 12 in the nonobese diabetics
and chromosome 18 in the obese diabetics (data not
shown). When paternal transmission to nonobese dia-
betics was considered, the LOD score on chromosome
12q was 2.41, with the framework marker set at marker
D12S79, a shift of 5 cM from the peak marker. Inclusion
of the additional 21 microsatellite markers in the anal-
Figure 3 a, Positive interaction between the loci on chromosomes 5 and 12. Multipoint allele-sharing LOD score of a portion of chromosome
12 after 21 microsatellite markers have been added to the framework marker set. Results are shown for all nonobese diabetics (black line) and
for nonobese diabetics in positive-NPL families on chromosome 5 (red line). b, Negative interaction between the loci on chromosomes 5 and
10. Multipoint allele-sharing LOD score of a portion of chromosome 10 after 8 microsatellite markers have been added to the framework
marker set. Results are shown for all nonobese diabetics (black line) and for nonobese diabetics in negative-NPL families on chromosome 5
(blue line).
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Figure 4 The effects of imprinting on the LOD score on chromosome 5. Maternal versus paternal effect on chromosome 5 locus. Results
are shown for all nonobese diabetics (black line), nonobese diabetics with maternal inheritance (red line), and nonobese diabetics with paternal
inheritance (blue line).
ysis resulted in a decrease in the LOD score to 1.43 and
a shift of the peak to D12S157, ∼2 cM from the peak
marker. However, analysis of the maternal transmission
resulted in no linkage to this chromosomal region. An
interesting observation came from the effect of imprint-
ing on the linkage analysis on chromosome 18p: ma-
ternal transmission to obese diabetics resulted in an in-
crease in the LOD score to 2.48 at marker D18S1132,
which is a shift of 4.5 cM from the peak marker obtained
in all obese diabetics. No linkage was observed when
the paternal transmission was considered.
Discussion
A number of genomewide scans for T2D have been per-
formed using different ethnic groups yielding several sig-
nificant and suggestive T2D susceptibility loci. The ge-
nomewide scan using nonobese type 2 diabetics in
Iceland resulted in a linkage to chromosome 5q34–q35.2
with a LOD score of 3.64 ( ). The cor-5Pp 2.12# 10
responding LOD score for the obese type 2 diabetics
was 0.2 ( ) and for the whole patient cohort thePp .17
LOD score was 2.90 ( ). Note however4Pp 1.29# 10
that these LOD scores, and the corresponding P values,
have not been corrected for the number of phenotypes
analyzed and the significance should be interpreted
accordingly.
Obesity, which is controlled by both genetic and en-
vironmental factors, is strongly associated with diabe-
tes. In fact, 40% of the diabetics in Iceland are obese,
which is more than twice the population prevalence of
obesity (17%). Thus, we reasoned that by fractionating
the patient group into nonobese and obese study groups,
we might (1) decrease the effects of genetic and envi-
ronmental factors that contribute directly to obesity but
only indirectly to T2D and (2) perhaps select for indi-
viduals with primarily beta cell dysfunction, as they did
not need as severe a level of obesity to unmask their
diabetes. Suggestive evidence for linkage (LOD score
12.2) was not observed when the obese diabetic study
group was used. However, the strongest linkage for that
group was to chromosome 18, with a LOD score of
1.31 at marker D18S63, corresponding approximately
to a previously reported linkage for obese type 2 dia-
betics in Scandinavia (Parker et al. 2001).
Previously published T2D genomewide scans have
not demonstrated a suggestive linkage to 5q35. There
are, however, few reports that have documented nom-
inal linkage to regions that are either just centromeric
or telomeric to the locus. Elbein et al. (1999), Vionnet
et al. (2000), and Lindgren et al. (2002a) all noted a
weak linkage centromeric to our peak on chromosome
5, using as affected subjects individuals with T2D or
with T2D combined with glucose intolerance. In a re-
port on early-onset diabetes (Lindgren et al. 2002b), the
authors observe a weak linkage to an extensive region
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at the q arm of chromosome 5, a region that includes
our linkage peak. The subjects studied in these reports
are, like the Icelandic patients, white, although coming
from Utah (Elbein et al. 1999), France (Vionnet et al.
2000), Sweden, and Finland (Lindgren et al. 2002a;
Lindgren et al. 2002b). Further, Luo et al. (2001) have
shown some evidence for linkage to 5q in Chinese Hans
with T2D. Here, the linkage is telomeric to the peak in
the Icelandic material. Also, a QTL analysis in Finns
(T2D and BMI) reports a weak linkage telomeric to the
Icelandic linkage peak but close to the linkage peak in
the Chinese Hans (Watanabe et al. 2000). The reported
linkage that best overlaps with the locus reported here
was observed in Pima Indians, in a study that used pre-
diabetic phenotypes (Pratley et al. 1998). Although
weak, the phenotype AIR (acute insulin response)
showed linkage to marker D5S820 (LOD scorep 0.70),
which is at the border of the 1.5-LOD drop within our
locus. It is close to marker D5S2049 in our map (see
deCODE Genetics Web site). AIR is a measurement of
insulin secretion, and a low AIR is a predictor of T2D
in insulin-resistant Pima Indians (Thompson et al.
1995). In none of the studies was the patient material
fractionated according to our criteria, with the excep-
tion of the study by Watanabe et al. (2000), who strat-
ified the diabetics according to BMI in their QTL anal-
ysis. The only report describing linkage to this region
on chromosome 5 that completely overlaps with the
Icelandic locus is in a recently published paper (Frayling
et al. 2003) that describes a genomewide scan in families
of European descent with MODY (the multipoint NPL
Z score was 2.04; D5S400–D5S498). The use of dif-
ferent populations as well as different marker orders
could explain why the peaks are spread over a consid-
erable area. It is also possible that there is more than
one gene on the telomeric arm of chromosome 5q that
contributes to diabetes.
It has been suggested that the effects of imprinting
on the genetics of a complex disease such as diabetes
have been underestimated. However, some fragmentary
data do exist, showing significant effects of imprinting
on the development of T2D. Thus, T2D was reported
to be associated with paternally derived alleles in the
VNTR of the insulin promoter (Huxtable et al. 2000).
Transient neonatal diabetes mellitus (TNDM) is asso-
ciated with a duplication of a segment of chromosome
6 when the duplication is of paternal origin (Gardner
et al. 1999). Low birth weight predisposes to devel-
opment of T2D (Barker et al. 1993). Some of the genes
that are known to affect fetal growth, including IGF2,
are predominantly paternally expressed (Huxtable et al.
2000). Our analysis of the nonobese diabetes locus on
chromosome 5 suggests that imprinting could play a
role. The LOD score was 3.48 when maternal trans-
mission was considered but was only 0.53 when the
paternal transmission was considered. The observation
for chromosome 12 was reversed, in that a higher LOD
score was obtained when a paternal transmission was
considered than when a maternal transmission was con-
sidered. In the obese diabetics, a maternal transmission
was observed for the locus on chromosome 18p. One
genomewide analysis in Pima Indians explored the ef-
fects of imprinting on the inheritance of diabetes and
BMI (Lindsay et al. 2001). None of their loci met criteria
for genomewide significance, but, using maternally de-
rived alleles, they observed linkage to age-adjusted di-
abetes on chromosome 5, near our locus.
Mahtani et al. (1996) reported evidence for linkage
to 12q24. The HNF1a (TCF1) gene resides within this
locus and mutations in this gene have been shown to
cause MODY3, a rare early-onset form of T2D. The
gene has been screened for association to late-onset
T2D; however, results have been negative (Shaw et al.
1998). Linkage to this region was detected in our dia-
betes material. First, using framework markers, we ob-
served a positive LOD score of 1.44 at 12q24, using
the nonobese diabetics. Second, the 12q24 locus inter-
acts positively with our major locus on chromosome 5,
and the linkage gained increased support by the addition
of more markers. When linkage analysis was performed
using the nonobese diabetes families with a positive
NPL scores on chromosome 5, the LOD score on 12q
increased from 1.47 to 2.26. These results suggest a
synergy between diabetes-susceptibility genes at 5q and
12q24.
The first and only polygene isolated for T2D through
positional cloning is the calpain 10 gene at 2q37 (Hor-
ikawa et al. 2000). The original linkage was observed
in Mexican Americans, but it has not been replicated
in white populations (Ciccarese et al. 1997; Hani et al.
1997; Thomas et al. 1997; Ghosh et al. 1999; Ehm et
al. 2000; Vionnet et al. 2000; Lindgren et al. 2002a),
including Icelanders (i.e., in the present study). Fur-
thermore, we have not been able to replicate the linkages
reported by others to chromosomes 20, 1q, 11q, 3q,
3p, or 15q. In the present genomewide scan, linkages
were observed to chromosomes 6q, 11q, 16q, and 19p
(LOD scores range from 1.0 to 1.8) in the nonobese
diabetics. There was a decrease in the linkage to 6q
when the locus on chromosome 5 was conditioned on.
Although some of these linkages could well be false-
positive results, some of these weak linkages overlap
with published results. The locus on 6q overlaps with
the one reported by Hanson et al. (1998) in diabetic
Pima siblings. They observed a linkage with a Z score
of 1.39. The locus on 11q in nonobese diabetics overlaps
somewhat with the Ghosh et al. (2000) locus on chr11
(1.75, additive model). The loci on chromosomes 16q
and 19p have not been reported by others. One of the
two loci observed in the obese diabetics overlaps with
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a previously published locus on 18p in Scandinavian
obese diabetics (Parker et al. 2001). The other locus on
chromosome 11p does not overlap with a previously
known locus.
Our results suggest that we have uncovered a locus
on chromosome 5q that contains a gene that contributes
to the development of T2D in nonobese Icelanders. This
gene appears to be imprinted and to interact with a
second locus on chromosome 12q.
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